Cefazolin in Dextrose Injection
Product details
- Cefazolin in Dextrose Injection
Company announcement
On July 24, 2026, Baxter International Inc. initiated a voluntary nationwide recall of Cefazolin in Dextrose Injection due to the presence of cardboard particulate matter found in the solution.
The affected product was distributed from March 25, 2025, to June 30, 2025, in the United States.
No adverse events have been reported to date.
Risk:
The use of the defective product has a reasonable probability of causing pulmonary emboli (blockage in pulmonary blood vessels), occlusions of other blood vessels (which can lead to tissue death and possible organ damage), and/or phlebitis (inflammation of the walls of veins, which may lead to clotting). Systemically, foreign particles infused intravenously can cause systemic activation of the immune system, organ dysfunction, and hemolysis (breakdown of blood cells).
Impacted states: Nationwide
Products:
- Cefazolin in Dextrose Injection, USP, 2g / 100mL (20mg / mL) Single-Dose Infusion Bag in 100mL GALAXY Plastic Container, Frozen Premix (UPC code(s): 0338350841)
Contact
For more information, call (888) 229-0001.